Apollo Tyres Ltd FY26 Results and Strategic Dividend Announcement

Apollo Tyres has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue of ₹284,706 million for the fiscal year, with a net profit of ₹13,724 million. Reflecting robust performance, the Board has recommended a final dividend of ₹2.50 per equity share, bringing the total dividend for FY26 to ₹6.00 per share.

Financial Performance for FY26

For the financial year ended March 31, 2026, Apollo Tyres delivered solid growth. The company achieved a consolidated revenue from operations of ₹284,706 million, compared to ₹261,234 million in the previous year. The consolidated net profit for the year stood at ₹13,724 million. For the final quarter (Q4) of FY26, the company reported consolidated revenue of ₹73,356 million and a net profit of ₹6,310 million.

Dividend Payout

The Board of Directors has recommended a final dividend of ₹2.50 per equity share (250% on a face value of Re. 1) for FY26. This follows an interim dividend of ₹3.50 per share already paid during the year, resulting in a total dividend payout of ₹6.00 per share (600%) for the financial year. The final dividend is subject to approval by shareholders at the upcoming Annual General Meeting.

Operational Highlights and Appointments

During the board meeting held on May 14, 2026, the company also finalized key administrative decisions. M/s. BBS & Associates has been appointed as the Cost Auditor for the financial year 2026-27. Furthermore, the board has recommended the re-appointment of Ms. Lakshmi Puri as an Independent Director for a second 5-year term, beginning October 29, 2026, pending shareholder approval.

Strategic Reorganization

The company continues to optimize its operations, including a significant restructuring effort at its Enschede plant in the Netherlands. The total financial impact related to this reorganization and closure-related provisions for the year ended March 31, 2026, amounted to ₹10,001 million. Additionally, the company has successfully adopted a new concessional tax regime, resulting in a net positive impact of ₹5,737 million recognized in the financial statements for the year.

Source: BSE

Previous Article

Akums Drugs and Pharmaceuticals Ltd Operations Impacted by Labour Unrest in Haridwar

Next Article

NATCO Pharma Limited Received Demand Notice from Pharmaceutical Pricing Authority